Flu Vaccine Effectiveness in Aging
(FluVax3 Trial)
Trial Summary
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications. However, if you are taking medicines that alter immune response, like high-dose corticosteroids, you may not be eligible to participate.
What data supports the effectiveness of the flu vaccine in preventing hospital admissions?
Is the flu vaccine safe for older adults?
How is the flu vaccine treatment unique compared to other treatments for flu prevention?
The flu vaccine treatment is unique because it involves multiple types of vaccines over three years, including high-dose and adjuvanted versions, which are specifically designed to enhance immune response in older adults, making it more effective for aging populations compared to standard flu vaccines.1112131415
What is the purpose of this trial?
This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 75 older adults (65 years and older) who will receive three different influenza vaccines over three annual influenza seasons. Blood samples will be collected from the participants at sixteen study visits over three years. Nasal swab and stool samples will also be collected from participants at seven time-points across the study period. The study is not designed to assess safety or tolerability of the influenza vaccines administered as part of this study.
Research Team
George Kuchel, MD, FRCP
Principal Investigator
UConn Center on Aging
Eligibility Criteria
This trial is for English-speaking men and women aged 65 or older, weighing at least 110 lbs, who are willing to participate in a three-year study involving 19 visits. Participants must be open to receiving annual flu vaccines and providing blood samples. They should not have severe reactions to past flu vaccines but cannot join if they've had Guillain-Barre syndrome after vaccination, recent other vaccinations, egg allergies, certain chronic diseases, or conditions affecting the immune system.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Vaccination Year 1
Participants receive the Fluzone Quadrivalent High-Dose vaccine and undergo blood sampling for antibody and immune cell analysis
Vaccination Year 2
Participants receive the FLUAD Quadrivalent vaccine and undergo blood sampling for antibody and immune cell analysis
Vaccination Year 3
Participants receive the Flublok Quadrivalent vaccine and undergo blood sampling for antibody and immune cell analysis
Follow-up
Participants are monitored for immune response and effectiveness after each vaccination year
Treatment Details
Interventions
- Flu Vaccine (Year 1)
- Flu Vaccine (Year 2)
- Flu Vaccine (Year 3)
Flu Vaccine (Year 1) is already approved in United States, European Union, Canada, Japan for the following indications:
- Prevention of influenza A and B in individuals 65 years and older
- Prevention of influenza A and B in adults 65 years and older
- Prevention of influenza A and B in individuals 6 months and older, including those 65 years and older
- Prevention of influenza A and B in individuals 6 months and older, including those 65 years and older
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Jackson Laboratory
Lead Sponsor
University of Chicago
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
UConn Health
Collaborator
Icahn School of Medicine at Mount Sinai
Collaborator
Weill Medical College of Cornell University
Collaborator